Summary
This 2017 study conducted a functional genetic screen in FGFR-mutant urothelial carcinoma cells to identify molecular mechanisms underlying resistance to FGFR inhibitors. The research identified the phosphoinositide 3-kinase signalling pathway as a significant determinant of resistance. The findings suggest that pathway profiling may inform strategies to overcome therapeutic resistance in FGFR-driven bladder cancers.
UK applicability
As a fundamental cancer cell biology study, the findings have potential relevance to UK oncology practice and drug development, though clinical translation would require validation in patient cohorts and prospective trials conducted within UK healthcare systems.
Key measures
Genetic screen results identifying resistance pathways; phosphoinositide 3-kinase pathway activation status; FGFR inhibitor sensitivity assays in urothelial cell carcinoma lines
Outcomes reported
The study employed a functional genetic screen to identify signalling pathways conferring resistance to FGFR inhibitors in FGFR-mutant urothelial cancer cells. The research focused on characterising the phosphoinositide 3-kinase pathway as a key determinant of therapeutic resistance.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.